Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 24, 2025

Phospho-TIF1-beta (Ser824) Antibody

RRID:AB_2209906
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 4127, RRID:AB_2209906)

Antibody Information

URL: http://antibodyregistry.org/AB_2209906

Proper Citation: (Cell Signaling Technology Cat# 4127, RRID:AB_2209906)

Target Antigen: TRIM28

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: Phospho-TIF1-beta (Ser824) Antibody

Description: This polyclonal targets TRIM28

Target Organism: human

Antibody ID: AB_2209906

Vendor: Cell Signaling Technology

Catalog Number: 4127

Record Creation Time: 20231110T045802+0000

Record Last Update: 20241115T085924+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-TIF1-beta (Ser824) Antibody.

No alerts have been found for Phospho-TIF1-beta (Ser824) Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Huang M, et al. (2023) FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Molecular cell, 83(15), 2810.

Sahgal P, et al. (2023) Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors. iScience, 26(11), 108169.

Egger T, et al. (2022) A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress. Scientific reports, 12(1), 5422.

Ka NL, et al. (2021) IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell reports, 37(12), 110138.